Dozens of patient advocacy groups are angry over an unusual move by a health insurer that recently began offering $500 debit cards to people who agree to switch psoriasis medicines after it ...

If you take Cosentyx, you already might have discovered ... than other companies – offering customers a $500 debit card to change to one of the drugs it prefers. The move by the $168 billion ...

In a letter to doctors in March, some plans run by Cigna Pharmacy said patients could receive a $500 debit card if they switch from Cosentyx to Taltz or an older biologic before Aug. 31 and then ...

Many patients with moderate-to-severe psoriasis retreated with Consentyx regained previous levels of efficacy after 16 weeks following a relapse during a treatment pause, according to a poster ...

WASHINGTON — Research from two separate studies showing year-long efficacy results of for ixekizumab and Cosentyx treatments for psoriasis were presented at a late-breaking research forum at the ...

Novartis has unveiled more positive phase 3 data for Cosentyx, this time in patients with non-radiographic axial spondyloarthritis (nr-axSpA). The Swiss drugmaker has strengthened Consentyx’s ...

Novartis has announced that the Scottish Medicines Consortium has approved Consentyx (secukinumab) to treat adults with active moderate-to-severe hidradenitis suppurativa (HS) in Scotland on the NHS.